The medication works the same regardless of which approved site you choose
What should I look for when evaluating these products
Lastly, the future positioning of dual GIP/GLP-1RA against GLP-1RA in the treatment landscape of T2D needs to be better defined
FDA Warning Letter September 9, 2025 The FDA issued a warning letter to Hims & Hers Health, Inc., dba Hers, dated September 9, 2025, regarding certain compounded semaglutide marketing claims
They are not as intimidating as they sound
The material from Koi is a research-grade lyophilized peptide vial with analytical documentation (HPLC, LC-MS, endotoxin) built around in vitro laboratory use, not patient-directed compounding, dispensing, or any clinical workflow